Replicel Life Sciences Inc (REPCF) 0.4900 $REPCF
RepliCel Retains Market-Making Services
Marketwire - Fri Sep 12, 6:00PM CDT
RepliCel Life Sciences Inc. (TSX VENTURE: RP)(OTCQB: REPCF) ("RepliCel" or the "Company"
has, subject to regulatory approval, retained Venture Liquidity Providers Inc. ("VLP" to initiate its market-making service to provide assistance in maintaining an orderly trading market for the common shares of the Company.
RepliCel Garners Feature on Fox Business News and the Financial Post
Marketwire - Tue Sep 09, 2:37PM CDT
RepliCel Life Sciences Inc.'s (TSX VENTURE: RP)(OTCQB: REPCF) CEO, David Hall, kicked-off his New York roadshow with a live appearance on Fox Business network's Varney & Co. following his presentation at Rodman & Renshaw's Annual Global Investment Conference. The two discussed the company's revolutionary products using an individual's own cells to treat sports and work related tendon injuries, sun damaged and aging skin and pattern baldness. The interview can be viewed online at http://www.foxbusiness.com/on-air/varney-co/i...5771951001.
New Technology Puts Your Own Cells to Work to Repair and Rejuvenate Your Body
ACCESSWIRE - Tue Sep 09, 1:11PM CDT
Vancouver, BC / September 9, 2014 / There is enormous interest in the worlds of medicine and esthetics in the promise of regenerative medicine. From cellular replacement techniques for treating Parkinson's disease to collagen-producing cell injections for wound healing and rejuvenating aging skin, significant steps are being made towards the commercialization of cell therapies. These changes are going to attract major industry players who are constantly on the watch for the latest technologies in development.
Cutting-Edge Advancements: New Technology Puts Your Own Cells to Work to Repair and Rejuvenate Your Body
ACCESSWIRE - Tue Sep 09, 8:04AM CDT
Vancouver, BC / ACCESSWIRE / September 9, 2014 / There is enormous interest in the worlds of medicine and esthetics in the promise of regenerative medicine. From cellular replacement techniques for treating Parkinson's disease to collagen-producing cell injections for wound healing and rejuvenating aging skin, significant steps are being made towards the commercialization of cell therapies. These changes are going to attract major industry players who are constantly on the watch for the latest technologies in development.
RepliCel to Present at Rodman & Renshaw's 16th Annual Global Investment Conference in New York
Marketwire - Thu Sep 04, 8:04AM CDT
RepliCel Life Sciences Inc. (OTCQB: REPCF)(TSX VENTURE: RP), a clinical stage regenerative medicine company focused on the development of autologous cell therapies, will be presenting at the Rodman & Renshaw Global Investment Conference at the New York Palace Hotel on Tuesday, September 9, 2014 at 9:15 A.M. local time in the Adam's Salon on the fourth floor.
RepliCel Life Sciences Joins Centre for Commercialization of Regenerative Medicine, Industry Consortium
Marketwire - Wed Sep 03, 6:01AM CDT
RepliCel Life Sciences Inc. (TSX VENTURE: RP)(OTCQB: REPCF), a clinical stage regenerative medicine company focused on the development of autologous cell therapies, is the newest member of the Centre for Commercialization of Regenerative Medicine's (CCRM) industry consortium.
RepliCel Announces 2014 Second Quarter Financial Results
Marketwire - Tue Aug 26, 7:04AM CDT
RepliCel Life Sciences Inc. (the "Company" or "RepliCel" (TSX VENTURE: RP)(OTCQB: REPCF), a regenerative medicine company developing proprietary autologous cell therapies for chronic tendinosis, aging and sun damaged skin and pattern baldness, today announced its operational and financial results for the second quarter ended June 30, 2014. All amounts included in this news release are expressed in Canadian dollars unless otherwise indicated. The Company's financial statements and management report are available at www.edgar.com, www.sedar.com and at www.replicel.com.
RepliCel Appoints Brooke Hurford as Corporate Secretary and Director, Finance
Marketwire - Wed Jul 16, 8:00PM CDT
RepliCel Life Sciences Inc. (the "Company" (TSX VENTURE: RP)(OTCQB: REPCF), today announced that it has appointed Brooke Hurford, CA as Corporate Secretary and Director, Finance.
RepliCel Retains O&M Partners to Coordinate North American Focused Investor Marketing Campaign
Marketwire - Fri Jun 20, 4:00PM CDT
RepliCel Life Sciences Inc. (TSX VENTURE: RP)(OTCQB: REPCF), today announced that it has retained O&M Partners, LLC to assist in targeting non-deal institutional and independent money managers throughout the United States including financial centres often overlooked by biotech companies. This marketing effort will include a combination of group Town Hall conference calls and follow-up roadshows. With the commencement of three human clinical trials before year-end, management is dedicated to meeting as many non-deal investors as possible. This campaign is an integral part of the company's overall marketing effort focused on the United States.
Ubika Research Publishes Research Report on RepliCel Life Sciences Inc. (TSXV: RP)
PR Newswire - Thu Jun 19, 8:59AM CDT
Ubika Research has recently published a new information report on RepliCel Life Sciences Inc. (TSXV: RP) (OTCQB: REPCF), a regenerative medicine company focused on developing autologous cell therapies for multi-billion dollar markets that address diseases caused by a deficit of healthy cells required for normal healing and function, such as chronic tendinosis, damaged skin and pattern baldness.
RepliCel Life Sciences Announces Closing of Third and Final Tranche of Private Placement
Marketwire - Wed Jun 18, 1:29AM CDT
RepliCel Life Sciences Inc. ("RepliCel" or the "Company" (TSX VENTURE: RP)(OTCQB: REPCF), is pleased to announce it has completed the third and final tranche of its non-brokered financing (the "Financing" announced on March 28, 2014, which consisted of a non-brokered private placement of 866,000 units (each a "Unit" at a price of $0.75 per Unit for gross proceeds of $649,500 (the "Offering" . The total final gross proceeds for the Unit offering were $3,990,125.25. Each Unit consists of one common share of the Company (each, a "Share" and one Share purchase warrant (the "Warrant" , which will entitle the holder to purchase one additional Share for a period of two years from the closing of the private placement at a price of $1.00 per Share during the first year and $1.25 per Share during the second year. This financing was led by Crossover Healthcare Fund, LLC.
RepliCel Retains Market-Making Services
Marketwire - Fri Sep 12, 6:00PM CDT
RepliCel Life Sciences Inc. (TSX VENTURE: RP)(OTCQB: REPCF) ("RepliCel" or the "Company"
has, subject to regulatory approval, retained Venture Liquidity Providers Inc. ("VLP" to initiate its market-making service to provide assistance in maintaining an orderly trading market for the common shares of the Company. RepliCel Garners Feature on Fox Business News and the Financial Post
Marketwire - Tue Sep 09, 2:37PM CDT
RepliCel Life Sciences Inc.'s (TSX VENTURE: RP)(OTCQB: REPCF) CEO, David Hall, kicked-off his New York roadshow with a live appearance on Fox Business network's Varney & Co. following his presentation at Rodman & Renshaw's Annual Global Investment Conference. The two discussed the company's revolutionary products using an individual's own cells to treat sports and work related tendon injuries, sun damaged and aging skin and pattern baldness. The interview can be viewed online at http://www.foxbusiness.com/on-air/varney-co/i...5771951001.
New Technology Puts Your Own Cells to Work to Repair and Rejuvenate Your Body
ACCESSWIRE - Tue Sep 09, 1:11PM CDT
Vancouver, BC / September 9, 2014 / There is enormous interest in the worlds of medicine and esthetics in the promise of regenerative medicine. From cellular replacement techniques for treating Parkinson's disease to collagen-producing cell injections for wound healing and rejuvenating aging skin, significant steps are being made towards the commercialization of cell therapies. These changes are going to attract major industry players who are constantly on the watch for the latest technologies in development.
Cutting-Edge Advancements: New Technology Puts Your Own Cells to Work to Repair and Rejuvenate Your Body
ACCESSWIRE - Tue Sep 09, 8:04AM CDT
Vancouver, BC / ACCESSWIRE / September 9, 2014 / There is enormous interest in the worlds of medicine and esthetics in the promise of regenerative medicine. From cellular replacement techniques for treating Parkinson's disease to collagen-producing cell injections for wound healing and rejuvenating aging skin, significant steps are being made towards the commercialization of cell therapies. These changes are going to attract major industry players who are constantly on the watch for the latest technologies in development.
RepliCel to Present at Rodman & Renshaw's 16th Annual Global Investment Conference in New York
Marketwire - Thu Sep 04, 8:04AM CDT
RepliCel Life Sciences Inc. (OTCQB: REPCF)(TSX VENTURE: RP), a clinical stage regenerative medicine company focused on the development of autologous cell therapies, will be presenting at the Rodman & Renshaw Global Investment Conference at the New York Palace Hotel on Tuesday, September 9, 2014 at 9:15 A.M. local time in the Adam's Salon on the fourth floor.
RepliCel Life Sciences Joins Centre for Commercialization of Regenerative Medicine, Industry Consortium
Marketwire - Wed Sep 03, 6:01AM CDT
RepliCel Life Sciences Inc. (TSX VENTURE: RP)(OTCQB: REPCF), a clinical stage regenerative medicine company focused on the development of autologous cell therapies, is the newest member of the Centre for Commercialization of Regenerative Medicine's (CCRM) industry consortium.
RepliCel Announces 2014 Second Quarter Financial Results
Marketwire - Tue Aug 26, 7:04AM CDT
RepliCel Life Sciences Inc. (the "Company" or "RepliCel"
(TSX VENTURE: RP)(OTCQB: REPCF), a regenerative medicine company developing proprietary autologous cell therapies for chronic tendinosis, aging and sun damaged skin and pattern baldness, today announced its operational and financial results for the second quarter ended June 30, 2014. All amounts included in this news release are expressed in Canadian dollars unless otherwise indicated. The Company's financial statements and management report are available at www.edgar.com, www.sedar.com and at www.replicel.com. RepliCel Appoints Brooke Hurford as Corporate Secretary and Director, Finance
Marketwire - Wed Jul 16, 8:00PM CDT
RepliCel Life Sciences Inc. (the "Company"
(TSX VENTURE: RP)(OTCQB: REPCF), today announced that it has appointed Brooke Hurford, CA as Corporate Secretary and Director, Finance. RepliCel Retains O&M Partners to Coordinate North American Focused Investor Marketing Campaign
Marketwire - Fri Jun 20, 4:00PM CDT
RepliCel Life Sciences Inc. (TSX VENTURE: RP)(OTCQB: REPCF), today announced that it has retained O&M Partners, LLC to assist in targeting non-deal institutional and independent money managers throughout the United States including financial centres often overlooked by biotech companies. This marketing effort will include a combination of group Town Hall conference calls and follow-up roadshows. With the commencement of three human clinical trials before year-end, management is dedicated to meeting as many non-deal investors as possible. This campaign is an integral part of the company's overall marketing effort focused on the United States.
Ubika Research Publishes Research Report on RepliCel Life Sciences Inc. (TSXV: RP)
PR Newswire - Thu Jun 19, 8:59AM CDT
Ubika Research has recently published a new information report on RepliCel Life Sciences Inc. (TSXV: RP) (OTCQB: REPCF), a regenerative medicine company focused on developing autologous cell therapies for multi-billion dollar markets that address diseases caused by a deficit of healthy cells required for normal healing and function, such as chronic tendinosis, damaged skin and pattern baldness.
RepliCel Life Sciences Announces Closing of Third and Final Tranche of Private Placement
Marketwire - Wed Jun 18, 1:29AM CDT
RepliCel Life Sciences Inc. ("RepliCel" or the "Company"
(TSX VENTURE: RP)(OTCQB: REPCF), is pleased to announce it has completed the third and final tranche of its non-brokered financing (the "Financing" announced on March 28, 2014, which consisted of a non-brokered private placement of 866,000 units (each a "Unit" at a price of $0.75 per Unit for gross proceeds of $649,500 (the "Offering" . The total final gross proceeds for the Unit offering were $3,990,125.25. Each Unit consists of one common share of the Company (each, a "Share" and one Share purchase warrant (the "Warrant" , which will entitle the holder to purchase one additional Share for a period of two years from the closing of the private placement at a price of $1.00 per Share during the first year and $1.25 per Share during the second year. This financing was led by Crossover Healthcare Fund, LLC. 
